Osivax said its lead influenza vaccine failed in a Phase 2b trial, prompting a pivot to a combination strategy. After the unsuccessful mid-stage readout, the French biotech plans to pair the failed program with existing flu shots rather than continue as a standalone vaccine. The company’s decision reflects the difficult translation from immunogenicity signals to trial efficacy outcomes in seasonal vaccine development. Osivax also framed the pivot as preserving hope for the underlying approach through combination immunology. The Phase 2b program details were not included in the brief, but the pivot indicates a near-term shift in clinical strategy while maintaining program-level optionality.